During the early days of my diagnosis, I didn’t want people to be sad. Yes, my diagnosis was not a cause for celebration, but sadness was not going to change it. If I could be positive, especially in my view of the future, I might help others be less…
A Phase 2b clinical trial testing NP-120 (ifenprodil) as a treatment for chronic cough is expected to begin later this year, according to the therapy’s developer, Algernon Pharmaceuticals. But plans for a Phase 2b study of NP-120 in people with idiopathic pulmonary fibrosis (IPF) are postponed “until…
Changes in blood levels of Krebs von den Lungen-6 — a protein produced by certain lung cells and known as KL-6 — can help predict the risk of disease progression in people with idiopathic pulmonary fibrosis (IPF) who’ve been treated with the anti-fibrotic medicines Esbriet (pirfenidone) and Ofev (nintedanib),…
What a busy but blessed year 2022 was for me! I hope you all had a wonderful holiday season and are enjoying the first few days of the new year. When I was in college, someone told me that the older you get, the faster time passes. I didn’t believe…
Treatment with an extract of scorpion venom eased lung scarring in a mouse model of pulmonary fibrosis (PF), a study reported. The study, “Scorpion venom polypeptide governs alveolar macrophage M1/M2 polarization to alleviate pulmonary fibrosis,” was published in the journal Tissue and Cell. Scorpions and…
“You have idiopathic pulmonary fibrosis.” January marks six years since those five words changed my life. Late in 2022, I began a long overdue project renovating my home office, which had been delayed by procrastination. While doing so, I came across a journal I had started writing around the…
The Pulmonary Fibrosis Foundation (PFF) has added Cedars-Sinai Medical Center to its Care Center Network (CCN), a group of medical centers specializing in treating and supporting people with pulmonary fibrosis (PF). Cedars-Sinai is one of seven medical centers the foundation recently added to the network, bringing the total…
Last January, I started a column with the following: “’Every day is a new adventure!’ This is often my response when someone asks how I’m doing. It also seems appropriate when looking forward to what 2022 may hold for me.” Coincidentally, as I sat…
The Pulmonary Fibrosis Foundation (PFF) has added seven new medical centers to its Care Center Network (CCN) to improve pulmonary fibrosis (PF) patients’ nationwide access to specialized care. The expansion brings to 81 the number of care network facilities in 35 U.S. states. Six sites were added in…
Pliant Therapeutics’ experimental oral anti-fibrotic therapy bexotegrast has received orphan drug designation from the European Medicines Agency (EMA) as a potential treatment for idiopathic pulmonary fibrosis (IPF), the company announced. EMA gives this designation to therapies that have the potential to improve care for conditions that affect fewer…
Get regular updates to your inbox.
